In this article
Swiss drugmaker Novartis
on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as higher forecast peak sales for cancer drugs Kisqali and Scemblix offset losses from expiring patents.
Shares of the company rose about 1% in early trade. They have gained 16% so far this year.
Novartis has been on a $30 billion spending spree on acquisitions and licensing deals this year to bolster its pipeline ahead of patent expiries for its top-selling heart treatment Entresto and asthma drug Xolair.
